European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17–19, 2023, Barcelona, Spain - CRM - Centre de recherche en myologie - U974 Access content directly
Proceedings Neuromuscular Disorders Year : 2024

European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17–19, 2023, Barcelona, Spain

Hubert Smeets
Bram Verbrugge
  • Function : Author
Xavier Bulbena
  • Function : Author
Liliya Hristova
  • Function : Author
Isabelle van Beckhoven
  • Function : Author
Josephine Almekinders
  • Function : Author
Séverine Berreur
  • Function : Author
Karlijn Bouman
  • Function : Author
Xavier Bulbena
  • Function : Author
Laura de Bruin
  • Function : Author
Doris Feijen
  • Function : Author
Reghan Foley
  • Function : Author
Ana Rita Goncalves
  • Function : Author
Clara Gontijo Camelo
  • Function : Author
Marc Güell
  • Function : Author
Göknur Haliloğlu
  • Function : Author
Dwi Kemaladewi
  • Function : Author
Andrea Klein
  • Function : Author
Nastia Koleda
  • Function : Author
Olga Minko
  • Function : Author
Francina Munell
  • Function : Author
Tim Nebermann
  • Function : Author
Veronica Pini
  • Function : Author
Stefano Previtali
  • Function : Author
Andreas Roos
  • Function : Author
Markus Rüegg
  • Function : Author
Anna Sarkozy
  • Function : Author
Hubert Smeets
  • Function : Author
Jacek Stepniewski
  • Function : Author
Emma van Straten
  • Function : Author
Florence van Tienen
  • Function : Author
Susana Quijano-Roy
  • Function : Author
Bram Verbrugge
  • Function : Author
Nicol Voermans
  • Function : Author
Alexia West
  • Function : Author
Peter Yurchenco
  • Function : Author
Justin Moy
  • Function : Author
Cristina Almeida
  • Function : Author
Johannes Becker
  • Function : Author
Louise Gill
  • Function : Author

Abstract

The European Joint Programme on Rare Diseases (EJPRD) funded the workshop "LAMA2-Muscular Dystrophy: Paving the road to therapy", bringing together 40 health-care professionals, researchers, patient-advocacy groups, Early-Career Scientists and other stakeholders from 14 countries. Progress in natural history, pathophysiology, trial readiness, and treatment strategies was discussed together with efforts to increase patient-awareness and strengthen collaborations. Key outcomes were (a) ongoing natural history studies in 7 countries already covered more than 350 patients. The next steps are to include additional countries, harmonise data collection and define a minimal dataset; (b) therapy development was largely complementary. Approaches included LAMA2-replacement and correction, LAMA1-reactivation, mRNA modulation, linker-protein expression, targeting downstream processes and identifying modifiers, using viral vectors, muscle stem cells, iPSC and mouse models and patient lines; (c) LAMA2-Europe will inform patients (-representatives) worldwide on standards of care and scientific progress, and enable sharing experiences. Follow-up monthly online meetings and research repositories have been established to create sustainable collaborations.
Fichier principal
Vignette du fichier
2024.LAMA2 Barcelona.publication.pdf (363.52 Ko) Télécharger le fichier
Origin : Explicit agreement for this submission

Dates and versions

hal-04546346 , version 1 (15-04-2024)

Identifiers

Cite

Hubert Smeets, Bram Verbrugge, Xavier Bulbena, Liliya Hristova, Julia Vogt, et al.. European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17–19, 2023, Barcelona, Spain. LAMA2-muscular dystrophy: paving the road to therapy, Neuromuscular Disorders, 36, pp.16 - 22, 2024, ⟨10.1016/j.nmd.2024.01.001⟩. ⟨hal-04546346⟩
4 View
3 Download

Altmetric

Share

Gmail Facebook X LinkedIn More